

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CHINA BIOTECH SERVICES HOLDINGS LIMITED

中國生物科技服務控股有限公司

(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)

(Stock code: 8037)

ENTERING INTO A SITE ADMISSION AND INVESTMENT AGREEMENT IN RELATION TO THE BOAO LECHENG PILOT ZONE FOR A BNCT PROJECT

Reference is made to the announcement of China Biotech Services Holdings Limited (the “**Company**”) dated 19 November 2021 (the “**Announcement**”) in relation to the admission in principle of the BNCT (boron neutron) Cancer Treatment Centre Project initiated by the Company to the Boao Lecheng International Medical Tourism Pilot Zone of Hainan Free Trade Port, China. Unless otherwise specified, terms used in this announcement shall have the same meanings as those defined in the Announcement.

The Board announces that, on 28 February 2022, the Company, CBSH Flourish (Hong Kong) BNCT Medical Centre Limited (“**CBSH Flourish Hong Kong**”), a wholly-owned subsidiary of the Company and 鵬博(海南)硼中子醫療科技有限公司 (in English, for identification purpose only, CBSH Flourish (Hainan) BNCT Medical Technology Co., Ltd.) (“**CBSH Flourish Hainan**”), a non-wholly-owned subsidiary of the Company, entered into a site admission and investment agreement (the “**Agreement**”) with the Hainan Boao Lecheng International Medical Tourism Pilot Zone Administration (the “**Administration**”) in relation to the investment in and construction of a BNCT cancer treatment centre (the “**Centre**”) in the Boao Lecheng Pilot Zone.

Pursuant to the Agreement, the Administration will assist CBSH Flourish Hainan in completing the tender procedures for the site of the Project with the relevant land resource department and the site construction procedures. Upon completion, CBSH Flourish Hainan will acquire the land use right of approximately 9.26 mus of state-owned land within the area under the administration of the Administration as the site for the development and operation of the Project. The Administration will assist the Company and CBSH Flourish Hong Kong in understanding the status of the site of the Project as soon as possible, act as the direct liaison unit to assist in the procedures and approvals required for the Project, coordinate the various work in the Project, formulate relevant

zone policies based on the suggestions from the Company and CBSH Flourish Hong Kong for operational improvement, and provide subsidies for CBSH Flourish Hainan's national, provincial and city level scientific research projects carried out in the Project in accordance with the relevant policies and rules, amongst other things.

CBSH Flourish Hainan shall, in accordance with the Agreement, commence the construction of the Centre within six months from the date of acquisition of the land use right and complete the investment of no less than the specified amount in phases within thirty-six months from the date of acquisition of the land use right, and shall procure the Centre to meet the opening and operation conditions by then. CBSH Flourish Hainan shall meet certain targets in relation to operating revenue, tax expense, and bed utilization rates as stipulated in the Agreement beginning from the date of the Centre possessing the conditions for operation. In addition, CBSH Flourish Hainan shall put together a core team with the relevant core medical technology, whose members will work in the Boao Lecheng Pilot Zone and will be assessed by the Administration.

The Project is in line with the Company's development strategy of deploying precision treatment to patients in need. By introducing the most advanced BNCT equipment and medicines in the world, constructing the Centre in Boao, Hainan to take advantage of the pilot implementation and trial policies there, the Company is seeking to provide advanced and effective solutions to the treatment of solid tumors. This brings good news to patients.

By order of the Board
China Biotech Services Holdings Limited
Liu Xiaolin
Chairman and Executive Director

Hong Kong, 28 February 2022

As at the date of this announcement, the board of Directors comprises four executive Directors, namely, Mr. Liu Xiaolin (Chairman), Mr. He Xun, Mr. Huang Song and Mr. Wang Zheng; and three independent non-executive Directors, namely, Mr. Yan Guoxiang, Dr. Ho Ivan Chun Kit and Mr. Qian Hongji.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the “Latest Listed Company Information” page of the GEM website at www.hkgem.com for at least 7 days from the date of its publication and on the website of the Company at www.cbshhk.com.